

Development 133, 4381-4390 (2006) doi:10.1242/dev.02607

Developmental patterning of the cardiac atrioventricular canal by Notch and Hairy-related transcription factors

Joshua B. Rutenberg^{1,2}, Andreas Fischer³, Haibo Jia⁴, Manfred Gessler³, Tao P. Zhong⁴ and Mark Mercola^{1,*}

Mutations in Notch2, Jagged1 or homologs of the Hairy-related transcriptional repressor Hey2 cause congenital malformations involving the non-chamber atrioventricular canal (AVC) and inner curvature (IC) regions of the heart, but the underlying mechanisms have not been investigated. By manipulating signaling directly within the developing chick heart, we demonstrated that Notch2, Hey1 and Hey2 initiate a signaling cascade that delimits the non-chamber AVC and IC regions. Specifically, misactivation of Notch2 signaling, or misexpression of either Hey1 or Hey2, repressed *Bmp2*. Because Jagged (also known as Serrate in non-mammalian species) ligands were found to be present in prospective chamber myocardium, these data support the model that Notch2 and Hey proteins cause the progressive restriction of *Bmp2* expression to within the developing AVC and IC, where it is essential for differentiation. Misactivation or inhibition of Notch2 specifically induced or inhibited *Hey1*, respectively, but these manipulations did not affect *Hey2*, implicating *Hey1* as the direct mediator of Notch2. *Bmp2* within the developing AVC and IC has been shown to induce *Tbx2*, and we found that *Tbx2* misexpression inhibited the expression of both *Hey1* and *Hey2*. *Tbx2*, therefore, is envisaged to constitute a feedback loop that sharpens the border with the developing AVC and IC by delimiting *Hey* gene expression to within prospective chamber regions. Analysis of the loss-of-function phenotype in mouse embryos homozygous for targeted disruption of *Hey2* revealed an expanded AVC domain of *Bmp2*. Similarly, zebrafish *gridlock* (*Hey2* homolog) mutant embryos showed ectopic expression of *Bmp4*, which normally marks AVC myocardium in this species. Thus, *Hey* pathway regulation of cardiac *Bmp* appears to be an evolutionarily conserved mechanism to delimit AVC and IC fate, and provides a potential mechanistic explanation for cardiac malformations caused by mutations in *Serrate/Jagged1* and Notch signaling components.

KEY WORDS: Notch, Hairy-related transcription factor, HRT, HES, Hey, Gridlock, Atrioventricular canal, T-box, *Tbx*

INTRODUCTION

During early embryogenesis, the linear heart [HH stage 10 in the chick (Hamburger and Hamilton, 1951), E8 in the mouse] develops atrial and ventricular chamber myocardium as the heart tube loops (HH stage 13-16 in chick; E8.5-E9.0 in mouse) (reviewed by Fishman and Chien, 1997; Srivastava and Olson, 2000). Chamber myocardium goes on to acquire high gap-junction density, high conduction velocity, and, in ventricular myocardium, pronounced trabeculae. By contrast, the atrioventricular canal (AVC) and inner curvature (IC) regions proliferate more slowly and preserve the automaticity, poor intercellular coupling and slow contraction characteristics of the embryonic myocardium of the tubular heart (de Jong et al., 1992; Delorme et al., 1997; Icardo and Fernandez-Teran, 1987). These distinctive structural and conduction characteristics are essential for heart function and approximately 5% of all congenital heart defects (CHDs) in the newborn are attributed to improper development of AVC and IC-derived tissue (reviewed by Moorman and Christoffels, 2003).

Models for specification of chamber versus AVC and IC myocardial fate have begun to emerge that depend on the expression of specific combinations of transcription factors (Abdelwahid et al., 2001; Chan-Thomas et al., 1993; Davis et al., 2001; Habets et al., 2002; Kupersmidt et al., 1999; Yamada et al., 2000). In particular,

chamber-specific programs of gene expression depend on a cooperative interaction between *Tbx5* and the cardiac transcription factor *Nkx2.5*, whereas *Tbx2* inhibits *Tbx5*-dependent activation of chamber gene expression in the AVC and IC (Habets et al., 2002; Harrelson et al., 2004; Plageman and Yutzey, 2004; Stennard et al., 2003). Consequently, in the absence of *Tbx2*, the AVC and IC regions fail to constrict and express early chamber markers (Harrelson et al., 2004). *Tbx20* also cooperates with *Tbx5* and *Tbx2* in the regulation of chamber fate (Brown et al., 2005; Cai et al., 2005; Singh et al., 2005; Stennard et al., 2005; Takeuchi et al., 2005). Emerging evidence indicates that localized expression of *Bmp2* within the developing AVC and IC directs the spatiotemporal pattern of *Tbx2* transcription within the tubular heart (Yamada et al., 2000). Very little information exists on the signals that establish the spatial patterns of transcription factor expression that distinguish chamber from non-chamber myocardium other than *Bmp*, and the upstream signals that control *Bmp2* expression in the AVC and IC are largely unknown. Therefore, we tested whether Notch and *Hey* proteins are involved in the control of *Bmp2* and, hence, AVC and IC identity.

Notch receptors encode transmembrane proteins that control numerous cell fate decisions during vertebrate embryogenesis through cell-cell interactions (for a review, see Artavanis-Tsakonas et al., 1999). In mammals, four Notch receptors (Notch1-Notch4) recognize two classes of transmembrane ligands (Lardelli et al., 1994; Uyttendaele et al., 1996; Weinmaster et al., 1991; Weinmaster et al., 1992): Serrate [*Serrate*1 and 2, commonly termed Jagged in mammals (Lindsell et al., 1995; Shawber et al., 1996)] and Delta [comprising Delta-like1, 3 and 4 (Bettenhausen et al., 1995; Dunwoodie et al., 1997; Shutter et al., 2000)]. For canonical Notch signaling, the extracellular binding of ligand induces a presenilin-dependent cleavage of Notch that releases its intracellular domain (Notch_{ICD}) into the cytoplasm, where it forms a complex with the

¹Burnham Institute for Medical Research, 10901 N. Torrey Pines Road, La Jolla, CA 92037, USA. ²Biological and Biomedical Sciences Graduate Program, Harvard Medical School, Boston, MA 02115, USA. ³Theodor-Boveri-Institute, Physiological Chemistry I, University of Wuerzburg, D-97074 Wuerzburg, Germany. ⁴Departments of Medicine and Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.

*Author for correspondence (e-mail: mmercola@burnham.org)

DNA-binding protein CSL (CBF-1, Suppressor of Hairless, and Lag-2) (Honjo, 1996; Jarriault et al., 1995; Jeffries et al., 2002; Tamura et al., 1995) that in turn activates the transcription of target genes, such as the Hairy/Enhancer of Split (HES) family of transcriptional repressors, and the related *Hey1* and *Hey2* genes (see below).

Homozygous *CSL*^{-/-} mutants (Oka et al., 1995) and *presenilin1*^{-/-},*presenilin2*^{-/-} double mutants (Donoviel et al., 1999) die during mid-gestation with widespread cell death and underdeveloped hearts, in particular a thin, hypoplastic ventricular wall and impaired trabeculation. Overtly similar defects are seen in homozygous *Notch2* hypomorphs (Hamada et al., 1999; McCright et al., 2001) and *Notch1*^{-/-} (Conlon et al., 1995; Swiatek et al., 1994) embryos. Because CHDs often arise as consequences of malformations elsewhere in the developing embryo, the direct effects of Notch on myocardial development are not resolved by these systemic knockouts. Nonetheless, in humans, attenuated Notch activation causes Alagille syndrome (AGS), an autosomal dominant disorder characterized by CHDs, as well as cholestasis, vertebral and eye abnormalities, distinctive facial features, renal disease and growth retardation (Krantz et al., 1997). The CHDs range from mild to severe and can include tetralogy of Fallot, pulmonary artery stenosis, pulmonary atresia, truncus arteriosus, and ventricular and atrial septal defects. Jagged1 mutations leading to haploinsufficiency cause the syndrome in humans (Li et al., 1997; Oda et al., 1997) and AGS is phenocopied in the mouse by a reduction of *Notch2* function in a heterozygous *Jagged1*^{+/-null} background (McCright et al., 2002).

Hey1 and *Hey2* (also known as HRT2, CHF1, HESR2, HERP1 and gridlock) are highly expressed in the developing heart and vasculature (Chin et al., 2000; Kokubo et al., 1999; Leimeister et al., 1999; Nakagawa et al., 1999; Zhong et al., 2000). In mammals, these proteins are often referred to as Hairy-related transcriptional repressors (HRT1 and HRT2, respectively) and the zebrafish homolog of *Hey2* is the product of *gridlock*. Hey proteins have conserved basic helix-loop-helix (bHLH) and orange domains, and a YRPW motif near the C terminus that differs from the WRPW motif found in the structurally related HES proteins (reviewed by Fischer and Gessler, 2003; Iso et al., 2003). Disruption of *Hey2* in mice causes ventricular septal defects that are occasionally accompanied by other CHDs and cardiomyopathy (Donovan et al., 2002; Gessler et al., 2002; Sakata et al., 2002). *Hey1*^{-/-} mice lack apparent cardiovascular phenotypes, but the spectrum of *Hey2*^{-/-} anomalies is extended in double *Hey1/Hey2* homozygous mutants to include a ubiquitous angiogenic remodeling deficit and strongly impaired arterial endothelial development, leading to death by E10.5 (Fischer et al., 2004).

Here, we show that *Hey1* and *Hey2* repress *Bmp2* transcription in chick myocardium, thereby delimiting expression to within the developing AVC and IC as heart looping occurs. Hey-mediated repression of cardiac *Bmp* genes appears to be evolutionarily conserved in mice and zebrafish, as we observed ectopic cardiac *Bmp* transcription in mouse and zebrafish embryos with a disrupted *Hey2* homolog. In addition, using the chick system, we provide evidence for a feedback mechanism whereby *Tbx2*, which is induced by *Bmp2*, inhibits both *Hey1* and *Hey2* expression, and we propose that this mechanism sharpens the border of *Bmp2* transcription where chamber myocardium abuts the AVC and IC. Although both *Hey1* and *Hey2* suppress early cardiac *Bmp2*, we find that only *Hey1* responds to *Notch2* in chick hearts, thus leading to the model that segregation of prospective atrial and ventricular myocardium from AVC and IC regions by Hey proteins occurs in both a Notch-dependent and -independent manner.

MATERIALS AND METHODS

Organ culture and electroporations

Chick eggs were obtained from commercial sources and were incubated at 38.5°C for 30–56 hours until they reached HH stage 10–16 [staging according to Hamburger and Hamilton (Hamburger and Hamilton, 1951)]. Embryos were explanted in Tyrode's solution, and the heart surgically removed with a sharpened Tungsten needle. Hearts were then placed in 1×PBS with 200 ng/μl expression plasmid and transferred to a BTX372 electrode chamber (Genetronics). An ECM 830 Electro Square Porator was used to generate square pulses (2×20 V, pulse length 50 msec) before reversing electrode poles and repeating. Hearts were then incubated in 5% CO₂ at 37°C for 24 hours in culture media [α-MEM (Gibco), supplemented with 15% donor calf serum (Gibco), 5% chick serum (Gibco), 75 U/ml penicillin/streptomycin (Gibco), 10 mM HEPES buffer (Omega Scientific), and 0.3% L-glutamine (Gibco)]. Hearts were then fixed in 4% paraformaldehyde for 2 hours at room temperature and stored in 100% methanol at -20°C until they were processed for histology.

Expression plasmids

Each cDNA was cloned into pRS2, a modified pCS2 expression vector, in which the CMV promoter element was excised and an RSV promoter element cloned into the *Sall/HindIII* sites upstream of the multi-cloning site. Each cDNA was inserted into the pRS2 multi-cloning site as follows: pRS2-CSL-VP16, CSL-VP16-Myc, *BamHI/XbaI* (generous gift of J. Sklar, Brigham and Women's Hospital, MA, USA); pRS2-GFP (Myc-GFP, *BamHI/XbaI*); pRS2-Mfng, Man3HA, *HindIII/XbaI* (generous gift of T. Vogt, Merck Research Laboratories, West Point, PA, USA); pRS2-*Hey2*, *FlagHrt2*, *HindIII/XhoI* (generous gift of D. Srivastava, University of California, San Francisco, CA, USA); and pRS2-N₂ICD, *BamHI/StuI* (generous gift of T. Maciag). To fuse PCR cloned mouse *Hey1* to a 5' Myc epitope in the pRS2 vector, R-GFP was cut with *EcoRI* and *XbaI* to excise GFP, and mouse *Hey1* was inserted in frame at these sites.

To clone chick *Hey2*, *HES* and *Notch* cDNA, total RNA was prepared from HH stage 12–16 chick heart explants using TriZol reagent (Gibco) and the following degenerate primer pairs, where B=C,G,T; D=A,G,T; H=A,C,T; M=A,C; N=A,C,G,T; R=A,G; V=A,C,G; W=A,T; Y=C,T:

Hey2, 5'-CCCCGCGATCCAAYAGYTTGTCTGARCTG-3' and 5'-CCCCGCGCGCCCAAGGYCTRTAGGGYTT-3';

Hes, 5'-CCCCGCGATCCAAYAGYTTGTCTGARCTG-3' or 5'-CCCGCGGATCCCARATGACWGTGGAYCAC-3', and 5'-CCCCGCGG-CCCGGTGRTCCACWGTTCATYTG-3' or 5'-CCCCGCGCGCCCAAGGYCTRTAGGGYTT-3'; and

Notch, 5'-TGATBCTYGGCHRCBMGVYTGCHGT-3' and 5'-TTM-ACVGCNGCNGCCARTGNARDGC-3'.

To clone mouse *Hey1*, PCR was performed on the Mouse Brain Marathon-Ready cDNA library (Clontech). The 5' primer (5'-ATG-AAGCGCCCTTGTGAGG-3') includes the mouse *Hey1* translational start codon, and the 3' primer (5'-TTAAAGGCTCCAACCTTCTG-3') includes the mouse *Hey1* stop codon UAA.

In situ hybridization and epitope staining

Chick heart whole-mount in situ hybridization was performed as described previously (Levin et al., 1995), with the following modifications for combined in situ hybridization and immunohistochemistry. On day 1, after rehydration to PBT (PBS+0.1% TWEEN), hearts were incubated in RIPA wash with primary monoclonal antibodies against epitope tags for 45 minutes, followed by three 5-minute washes in PBT, a second 45-minute RIPA wash with Cy3-conjugated AffiniPure goat anti-mouse IgG diluted 1:100 (Jackson ImmunoResearch), and two 5-minute washes in PBT before fixation in 4% paraformaldehyde and 0.2% glutaraldehyde. Primary antibodies were anti-c-Myc 9E10 (Santa Cruz Biotechnology), anti-V5 antibody (Invitrogen), anti-HA HA.11 monoclonal antibody (Covance) and anti-FLAG M2 (Sigma), and each was diluted 1:100 in RIPA, with the exception of HA.11, which was diluted 1:1000 for immunohistochemistry.

Riboprobe templates for electroporated chick heart in situ hybridization were amplified from plasmids by PCR to eliminate the detection of plasmid DNA sequences. Each 3' primer was made with an embedded T7 promoter element. Primer pairs were:

Bmp2, 5'-ATGTTCCGGGCTGAAGC-3' and 5'-GTAATACGACTCAC-TATAGGGCGATACACTCGCGGTG-3';

Hey1, 5'-ATCATCGAGAAGCGCCGCCGACCGCATC-3' and 5'-GAATTCTAATACGACTACTATAGGGAGGACCGATCTCAGTCCC-3';

Hey2, 5'-AACAGTTTGTCTGAGCTGAGGCGGCTGGTG-3' and 5'-GAATTCTAATACGACTACTATAGGGACACAGGAAGCAACGCTG-3'; and

Amhc, 5'-CGACGAGCGGGTCCAGCTTCTCCACTCC-3' and 5'-GAAAATAATACGACTACTATAGGGAGGCACCTTGACACGCCGC-3'.

Chick cDNAs for *Cx42* (E. C. Beyer, University of Connecticut, Farmington, CT, USA) and *Irx4* (C. Cepko, Harvard Medical School, Boston, MA, USA) were inserted in pBS, and *Anf* was PCR amplified from cDNA and inserted into pGEM T-easy. Both plasmids have T7 and T3 promoters flanking the inserts, so corresponding commercial primers were obtained for amplification of the template (IDT). All probes were transcribed using T7 RNA polymerase, with the exception of *Cx42*, which was transcribed with T3 RNA polymerase. Riboprobes for *Serrate1*, *Serrate2* and *Delta-like1* were made as described (Henrique et al., 1995; Laufer et al., 1997; Myat et al., 1996).

Mouse embryo whole-mount in situ hybridization was carried out as described previously (Leimeister et al., 1998). The riboprobe for mouse *Bmp2* was generated from a PCR fragment (GCGGGATCCGTTTGCC-CTGAAGCAGAGAC, GCGGAATTCTGACGCTTTTCTCGTTTGTG) cloned into pCS2. Zebrafish whole-mount in situ hybridization was performed as described previously (Zhong et al., 2000). The *Bmp4* riboprobe was as described (Chen et al., 1997).

Quantitative analyses

Quantification of the incidence of cells exhibiting altered gene expression after electroporation in each case reflects cumulative data over greater than three independent experiments. Identifying sample details were encoded prior to embedding and histological sections were scored by collaborators lacking knowledge of the experiments. Individual cells that expressed the electroporated transgenes (epitope-specific immunostain) were scored as having reduced, unchanged or elevated levels of the endogenous gene (in situ hybridization stain) relative to immediately neighboring cells. Thus, a cell in the midst of a patch of electroporated cells might show reduced expression relative to non-electroporated cells, but would be scored as unchanged relative to surrounding electroporated cells; thus, the analysis underestimates the magnitude of the effects observed.

The atrioventricular length of the *Bmp2* expression domain in mouse E9.5-E10.0 embryos was performed using ImageJ (National Institutes of Health, <http://rsb.info.nih.gov/ij>). AVC length was determined as a straight line in the center of the AVC. Head length was measured along a line drawn from the anterior limit of the olfactory pit to the back surface of the head, intersecting the posterior limit of the mesencephalon.

In situ hybridization and epitope staining

Following culture, samples were processed for combined in situ hybridization, to detect endogenous gene expression, and immunohistochemistry, to detect the epitope-tagged proteins expressed from the electroporated pRSV construct. For immunohistochemistry, embryos were fixed in 4% paraformaldehyde for 30 minutes at room temperature. Rabbit polyclonal antibody against Notch2_{icd} was used (Novus) with an alkaline phosphatase-conjugated secondary antibody, and detection was with BCIP/NBT a substrate.

RESULTS

Dynamic expression patterns of Notch2, Serrate1 and Serrate2 demarcate the borders of the atrioventricular canal and inner curvature

Three Notch ligands have been identified in the chick: *Serrate1*, *Serrate2* (Hayashi et al., 1996; Myat et al., 1996) and *Delta-like-1* (Henrique et al., 1995). *Serrate1* mRNA was detected as early as HH stage 10 throughout the heart tube (not shown), but by stage 12 expression was absent in the developing atrium/sinus venosus region

(Fig. 1A). Between stages 14 and 16, expression recedes from the AVC forming an abrupt boundary at both anterior and posterior borders, with *Serrate1* expression continuing to mark mature myocardium of the ventricle and atrium (Fig. 1B,C). Notably, *Serrate1* expression was less robust in the IC as well. *Serrate1* maintained strong atrial and ventricular expression at all stages examined (up to stage 24, Fig. 1; data not shown). *Serrate2* mRNA was detected in the developing heart from stage 16 (Fig. 1E-H), in the distal portion of the atrium overlapping the expression of *Serrate1*, where it remained at all stages examined. *Delta-like1* was not detected at any stage surveyed (not shown).

By stage 16, the *Serrate* expression patterns become complementary to that of *Bmp2*, which marks the developing AVC and IC (compare Fig. 1K,L with Fig. 1C,D,G,H). Thus, *Serrate* might distinguish chamber from AVC and IC myocardium by controlling the spatial domain of *Bmp2* expression.

Two Notch receptor homologs, Notch1 and Notch2, have been identified in chick (Hamada et al., 1999; Myat et al., 1996); however, only Notch2 was detected in the myocardium of the heart between HH stages 10 through 20 and is thus likely to mediate the *Serrate* signal. Low levels of Notch2 were first detected in the stage 10 linear heart tube, in particular within a smattering of cells in the ventral, presumptive ventricle and the center of the fusing, bilateral atria (Fig. 1M). As looping proceeds, prominent Notch2 expression encompasses the entire heart tube and persists through at least stage 20 (Fig. 1N-Q). Notch1 was not detected in the myocardium at these stages, as examined by immunohistochemistry, in situ hybridization or RT-PCR analysis (not shown).

Activation of the Notch pathway suppresses *Bmp2* gene expression


A whole-heart in vitro electroporation system was devised to study the effects of misexpressed Notch pathway components (Fig. 2). Explanted chick hearts from HH stage 12 embryos were electroporated with RSV promoter-based expression plasmids to direct production of exogenous proteins and then cultured for 24 hours to the point when age-matched embryos had developed to between HH stages 19 and 22. A panel of region-specific markers confirmed appropriate development of the hearts after the procedure. Exogenous protein was detected by immunohistochemistry against an epitope tag, and concurrent in situ hybridization revealed the effect on endogenous marker gene expression.

Paraffin sections of electroporated hearts revealed that ectopic Notch pathway activation in the AVC and IC suppressed *Bmp2* expression. Either a Myc-tagged, human CSL DNA-binding region-VP16 transactivator (CSL-VP16) or a V5 epitope-tagged Notch2_{icd} (Small et al., 2003) cell-autonomously decreased the level of *Bmp2* mRNA relative to that in surrounding cells in the AVC and IC (Fig. 3A,B). The response was quantified by scoring transfected cells as having either increased, decreased or similar levels of *Bmp2* relative to their surrounding neighbors, revealing reduced expression in 37.9% and 48.3% of CSL-VP16- or Notch2_{icd}-expressing cells, respectively (Fig. 3D). By contrast, a control plasmid containing GFP fused to a Myc tag (GFP) did not elicit a reproducible change in *Bmp2* expression (Fig. 3C,D). Notch activation suppressed *Bmp2* with similar efficacy at stages 12, 14 and 16 (Fig. 3E), indicating that competence persists throughout this time window and might contribute to the progressive shift in endogenous *Serrate* and *Bmp2* expression patterns.

It is important to emphasize that all samples in this and subsequent experiments were stripped of experimental identifiers and the identities encoded prior to embedding, so that histological

Fig. 1. *Serrate1* and *Serrate2* gene expression patterns correspond to the borders of the AVC and indicate prospective atrial and ventricular chamber myocardium.

(A-D) Stage 12-18 embryos were hybridized with a *Serrate1* antisense RNA probe. (A) Stage 12 embryos exhibit widespread *Serrate1* expression throughout the posterior heart with the anterior boundary at the outflow tract. The posterior border stops at the presumptive atrium and sinus venosus, but may include primitive AVC tissue (white arrowhead). (B,C) Between stages 14 and 16 expression becomes restricted to the common ventricle and atria with boundaries at the AVC (white arrowheads, C). (D) At stage 18, expression is strong in the ventricles and atria, forming distinct boundaries at both the anterior and posterior AVC border (white arrowheads). (E-H) Stage 12-18 embryos were hybridized with a *Serrate2* antisense RNA probe. (E,F) At early stages, 12 and 14, *Serrate2* is not detected in the heart. (G) *Serrate2* expression becomes apparent by stage 16 at the posterior-most region of the heart, corresponding to the distal atrium and sinus venosus (white arrowhead). (H) By stage 18, strong *Serrate2* expression is observed in the atria and sinus venosus, overlapping that of *Serrate1* (white arrowhead). (I-L) Stage 12-18 embryos were hybridized with the AVC marker *Bmp2* for comparison with the Notch ligands. (I,J) *Bmp2* is expressed in the posterior-most region of the heart, including the primitive AVC, atria and sinus venosus. The most anterior *Bmp2* expression appears to correspond to the posterior border of *Serrate1* expression (compare arrowheads in A,B and I,J). (J,K) Between stages 14 and 16, *Bmp2* expression is restricted to the AVC. Again, *Bmp2* expression appears complementary to that of *Serrate1* in the primitive ventricle, and to both *Serrate1* and *Serrate2* in the atria (compare arrowheads in K with C,G). (L) *Bmp2* mRNA persists in the AVC. (M-Q) Immunostaining against Notch2. (M) Notch2 is first detected in the linear heart tube in small patches in the ventral primitive ventricle and at the junction of the two horns of the primitive atria (white arrowheads). (N-Q) By Stage 12, Notch2 is present throughout the myocardium, where it remains at all stages examined. a, atrial region; avc, atrioventricular canal; ot, outflow tract; v, ventricular region.



preparation and scoring were performed blind. Moreover, our nearest neighbor analysis of single cells under-represented the magnitude of changes in gene expression, because cells in the midst of a cluster of transfected cells that all showed a similar response were scored as unchanged with respect to their neighbors, even though the entire cluster would be changed relative to untransfected cells.

Cardiac expression of *Hey1* and *Hey2* suppresses *Bmp2*

Endogenous *Hey1* and *Hey2* transcripts are localized to overlapping regions of *Serrate1* and *Serrate2* expression in the developing chick heart (compare Fig. 1 with Fig. 4) and are absent in the intervening AVC. *Hey2* expression was limited to the myocardium of the developing ventricle at all stages examined, in a similar pattern to that described in mouse (Fig. 4A,B). *Hey1* was expressed not only in the atrium, as in the mouse, but also in the myocardial wall of the ventricle (Fig. 4C,D). We were unable to detect other members of the HES family of bHLH proteins in the developing myocardium using RT-PCR and specific and degenerate oligonucleotide primer sets (not shown), and are unaware of reports of other HES family members in the myocardium of the linear heart. We therefore examined whether Hey proteins mediate Notch2 function in AVC and IC patterning. Misexpression of N-terminal Myc-tagged mouse

Hey1 by electroporation into HH stage 12 hearts, as before, and cultured for 24 hours, repressed *Bmp2* in 34.4% of the cells relative to neighbors (Fig. 4E,H). *Hey1* and *Hey2* show a 51.3% sequence identity at the protein level, with greater similarity in the bHLH and orange domains. Both proteins act as transcriptional repressors and recognize similar DNA motifs (Chin et al., 2000; Fischer and Gessler, 2003). As for *Hey1*, electroporation of Flag-tagged mouse *Hey2* reduced *Bmp2* expression in 33.2% of transfected cells, relative to neighbors (Fig. 4F,H). Thus, both *Hey1* and *Hey2* suppress *Bmp2*.

Notch directly activates *Hey1*, but not *Hey2*

Electroporation of HH stage 12 hearts with Notch pathway agonists CSL-Vp16 and Notch2_{ICD} induced strong activation of endogenous *Hey1* in the AVC and IC myocardium, with relative increases occurring in 50.0% and 33.6% of cells, respectively (Fig. 5A,B), implicating Notch signaling in direct activation of *Hey1*. Upregulation was also apparent in the ventricular region over endogenous expression levels, implying a dose-response mechanism (not shown). As before, misexpression of the control plasmid containing GFP had no effect (Fig. 5A). Surprisingly, endogenous *Hey2* transcripts were not induced by Notch pathway agonists (Fig. 5A). To test the effect of inhibiting *Serrate*/Notch2 signaling




Fig. 2. Plasmid electroporation of linear heart tubes. Stage 12 hearts were dissected, electroporated with RSV promoter cDNA constructs to direct production of epitope-tagged Notch pathway modulators or GFP (see Materials and methods). During the subsequent 24-hour culture period, the electroporated hearts looped and developed appropriate expression patterns of region-specific markers, including *Cx43*, *vmhc* and *amhc* in chamber myocardium, as well as *Bmp2* in the AVC. In addition, *Serrate1* and *Hey2* showed characteristic expression patterns. Inset in *Bmp2* panel shows Cy3 immunofluorescent detection of the Myc-epitope tag-labelled product of transfected eGFP gene. a, atrial region; avc, atrioventricular canal; ic, inner curvature; ot, outflow tract; v, ventricular region.

cell autonomously, we next introduced the Manic Fringe glycosyltransferase, which inhibits responsiveness to Serrate ligands in a highly selective and cell-autonomous manner (Shimizu et al., 2001; Weinmaster and Kintner, 2003). HA-tagged mouse Mfng expressed following electroporation into stage 12 hearts significantly reduced the level of endogenous *Hey1* transcripts in chamber myocardium (28.4% of transfected cells exhibited lowered levels of expression relative to nearest neighbors), whereas GFP misexpression had no effect (Fig. 5A,C). *Hey2* was unaffected by Notch pathway antagonists (Fig. 5A). These experiments indicate differential regulation of *Hey1* and *Hey2* in the linear heart tube.

From the preceding results, we predicted that loss of Notch alone should not cause the *Bmp2* expression domain to expand into the ventricular myocardium because of persistent *Hey2* expression. Accordingly, Mfng, which suppressed *Hey1*, failed to induce ectopic myocardial *Bmp2* transcripts (Fig. 5D). We conclude, therefore, that Notch2 signaling involving *Hey1*, as well as Notch2-independent signaling involving *Hey2*, delimit the AVC and IC domain of *Bmp2* transcription.

Notch and Hey proteins do not regulate the identity of chamber myocardium directly


Lineage choice by Notch can occur by suppressing and/or promoting differentiation, depending on context. Two early chamber markers, *Cx42* and *Anf*, were examined to determine whether Notch2-mediated suppression of AVC and IC fate was accompanied by a reciprocal stimulation of chamber identity, which would be apparent by cell-autonomous, ectopic activation of these genes in the AVC and IC region. Neither ectopic Notch pathway activation, nor ectopic mouse *Hey1* or *Hey2* affected either gene (Fig. 6). Thus, Notch2 in the myocardium suppresses AVC and IC fate, but another signal must specify chamber identity.

Repression of Hey genes by Tbx2

Several targeted disruption transgenic studies in mice indicate Tbx genes regulate *Hey1* and *Hey2* transcription. For instance, disruption of *Tbx5* caused a reduction in ventricular *Hey2* expression (Bruneau et al., 2001), and disruption of *Tbx20* caused an expansion of the *Tbx2* and a reduction of the *Hey1* (Stennard et al., 2005) domain. As *Bmp2*

Fig. 3. Notch pathway agonists inhibit *Bmp2* expression cell autonomously in the AVC and IC.

(A-C) Histological sections demonstrating that misactivation of Notch signaling suppresses *Bmp2*. Immunohistochemical staining (red fluorescence) detected epitopes on expressed proteins from the electroporated cDNAs: CSL-VP16 (A), Notch2_{ICD} (B) or GFP control (C). Brightfield images on the left show in situ hybridization (blue). Cy3 (red) and DAPI (blue) fluorescent images are shown on right. The center panels show brightfield images merged with the fluorescent Cy3 (red) staining of the epitope-tagged proteins. Red arrows indicate examples of cells with reduced *Bmp2* relative to neighbors, whereas yellow arrows indicate examples of unchanged cells. Scale bar in A: 50 μ M. (D,E) Quantification of cells scored for altered gene expression relative to neighboring cells after electroporation with the indicated cDNAs, scored from histological sections as in A-C. All sample identifiers were encoded prior to histological embedding so that tissue processing and scoring was performed blind (see Materials and methods). Data plotted are cumulative over greater than three trials. Note that Notch pathway activation suppresses *Bmp2* expression (D) and that *Bmp2* remains responsive throughout the period of heart looping (HH stages 12-16; E). Asterisks indicate statistical significance of the difference between the experimental modulation of Notch pathway and the control GFP ($P < 0.05$, χ^2 test).






Fig. 4. Ectopic Hey1 and Hey2 suppress *Bmp2* cell autonomously in the AVC and IC. (A-D) Examples of endogenous *Hey2* and *Hey1* mRNA expression in stage 16 and 18 embryos. Arrowheads denote the borders of mRNA expression. (A,B) *Hey2* expression is restricted to the developing ventricles at all stages examined, similar to patterns reported for the mouse. (C) Low levels of *Hey1* are detected throughout the myocardium of stage 16 chick hearts. (D) By stage 18, *Hey1* is detected in atrial and ventricular myocardium, but not AVC, as for expression of *Serrate1* (see Fig. 1). Arrowheads indicate the borders of Hey gene expression with the AVC. (E-G) *Bmp2* suppression by exogenously provided Myc-tagged mouse Hey1 and Flag-tagged mouse Hey2. Immunohistochemical staining (red fluorescence) detected epitopes on expressed proteins from the electroporated cDNAs, as in Fig. 3: Hey1 (E), Hey2 (F) or GFP control (G). Scale bar in E: 50 μ M. (H) Quantification was performed as for Fig. 3. Asterisk indicates statistical significance of a difference between the effect of Hey proteins and GFP control ($P < 0.05$, χ^2 test).

induces *Tbx2* (Yamada et al., 2000), repression of Hey by this factor would help sharpen the border of Hey transcription where chamber myocardium abuts the AVC and IC. To directly test this model, we misexpressed Myc-tagged *Tbx2* and *Tbx5* proteins in tubular hearts. The efficacy of our Myc-tagged *Tbx* constructs was verified by showing reciprocal effects on endogenous *Cx42* (the chick homolog of *Cx43*). As expected (e.g. Bruneau et al., 2001; Habets et al., 2002), electroporated *Tbx5* induced *Cx42*, whereas *Tbx2* repressed *Cx42* expression (not shown). Myc-tagged *Tbx2* introduced into the ventricular myocardium of HH stage 12 hearts caused a robust and cell-autonomous inhibition of *Hey2*, and a less pronounced but


significant reduction of *Hey1*, as indicated by a 36.6% and 15.7% incidence of reduced expression relative to neighboring cells, respectively (Fig. 7A-C). By contrast, *Serrate1* was unaffected by *Tbx2* (not shown), thus suggesting that the point of regulation lies downstream. We did not find a consensus T-box binding element (TBE) to be conserved within 10 Kb upstream of the start sites of transcription of the mouse, human or chick *Hey1* and *Hey2* genes, or in the first intron, nor did we find a consensus *Nkx* element (NKE), such as is often located near a TBE in *Tbx*-responsive cardiac genes (e.g. Habets et al., 2002; Small and Krieg, 2003). The electroporation data, together with the lack of conserved T-box response elements,

Fig. 5. Differential effects of Notch on *Hey1*, *Hey2* and *Bmp2*.

Stage 12 hearts were electroporated to misexpress modulators of the Notch pathway signaling, cultured for 24 hours and analyzed for effects on endogenous gene expression, as described in Fig. 3.

(A) Activation of the Notch pathway with Myc-tagged CSL-VP16 or *Notch2_{ICD}* increased the number of cells that expressed endogenous *Hey1*, relative to neighboring cells, and attenuation of Notch with HA-tagged *Mfng* caused a decrease in *Hey1*-positive cells. By contrast, Notch pathway agonists and antagonists did not affect *Hey2*

expression. (B,C) Histological sections demonstrating that misactivation of the Notch pathway (B) or inhibition of endogenous Notch responsiveness by *Mfng* (C) elicited reciprocal and cell-autonomous effects on endogenous *Hey1*. Scale bar: 25 μ m. (D) Attenuation of Notch signaling with *Mfng* did not cause a cell-autonomous effect on the expression of *Bmp2*, consistent with the observations that *Hey2* is not regulated directly by Notch (A) yet suppresses *Bmp2* (see Fig. 4). Asterisks in A,D indicate statistical significance of the difference between the Notch pathway modulators and the GFP control ($P < 0.05$, χ^2 test).






Fig. 6. Ectopic Notch2 signaling does not cause expansion of early chamber marker expression into the developing AVC or IC. Neither *Anf* nor *Cx42* was induced following ectopic Notch pathway activation by misexpression of Myc-tagged CSL-VP16 in stage 12 hearts or by Flag-tagged mouse *Hey1* and mouse *Hey2*. Analysis was as for preceding experiments.

strongly indicate that *Tbx* regulation of *Hey* genes involves an unknown intermediary, consistent with the finding that Myc-tagged *Tbx5* protein did not activate either *Hey* gene (Fig. 7A). Thus, we conclude that the activation of *Tbx2* by *Bmp2* is likely to suppress *Hey1* and *Hey2* in the AVC and IC, and might constitute a feedback circuit to sharpen the border of *Hey* gene expression.

Because *Tbx2* suppressed both *Hey1* and *Hey2*, we next investigated whether either *Hey* protein cell-autonomously suppresses *Tbx2*, constituting a mutually repressive interaction. As seen in Fig. 7D, *Tbx2* was unaffected by cell-autonomous expression of either *Hey* protein, indicating that *Hey* proteins suppress AVC and IC fate through the inhibition of *Bmp2* rather than by regulation of *Tbx2*. In addition, *Tbx2* is insufficient to maintain *Bmp2* expression cell autonomously, as cells expressing *Hey* proteins are always negative for *Bmp2*.

Expansion of the *Bmp2* domain in AVC/IC of mouse and zebrafish embryos lacking *Hey2* homologs

Having demonstrated that *Hey* proteins suppress *Bmp2* in chick AVC/IC, we tested whether loss of *Hey* function would cause a corresponding increase. As discussed above, *Hey2* (also known as *HRT2* in mammals) is the only *Hey* homolog transcribed in mouse ventricular myocardium (*Hey1* is atrial) and targeted disruption has not been correlated with early AVC defects. When E9.5 embryos were analyzed by in situ hybridization, however, we found a distinct increase in the *Bmp2* expression domain relative to that of wild-type littermates (Fig. 8A,B). The linear length of the domain along the atrioventricular axis of the heart was expanded approximately 1.7-fold, measured relative to either the head length of the embryo (Fig. 8C, $P=0.005$) or the maximal width of the mandibular arch (not shown, $P=0.005$) in order to normalize for natural variation in embryo size within a litter. Zebrafish *gridlock* (*grl*) is the only *Hey* homolog expressed in the dorsal aorta and the early looping heart, where transcripts are localized to ventricular and atrial myocardium (Fischer et al., 2002; Zhong et al., 2000) (H.J. and T.P.Z., unpublished). We examined the expression of *Bmp* genes in the early looping zebrafish heart at 48 hours postfertilization (hpf) and found that *Bmp4*, rather than *Bmp2*, shows AVC expression (Fig. 8D). *grl* mutants showed ectopic inflow tract expression of *Bmp4* and diffuse ventricular myocardial expression (Fig. 8E). Neither species showed measurable expansion of *Tbx2* homologs outside of the normal AVC expression domain (not shown), possibly reflecting




Fig. 7. *Tbx2* represses *Hey1* and *Hey2* cell autonomously.

(A) Misexpression of Myc-tagged *Tbx2* in stage 12 hearts caused a cell-autonomous reduction in the incidence of *Hey1*- and *Hey2*-positive cells. *Tbx5*, by contrast, had no effect. Asterisks indicate statistical significance of the difference between electroporated *Tbx2* and the GFP control ($P<0.05$, χ^2 test). (B,C) Histological sections demonstrating the cell-autonomous suppression of endogenous *Hey1* (B) and *Hey2* (C) by electroporated *Tbx2*. (D) Flag-tagged mouse *Hey1* and mouse *Hey2* did not alter *Tbx2* expression. Brightfield, merged and fluorescent images are as in Fig. 3. Scale bar: 50 μ m.

overriding repression by *Tbx20* in ventricular myocardium (Brown et al., 2005; Cai et al., 2005; Singh et al., 2005; Stennard et al., 2005; Takeuchi et al., 2005).

DISCUSSION

Recent evidence suggests that *Tbx2* in the developing chambers of the linear to early looping heart cooperates with the more broadly expressed transcription factors *Nkx2.5* and *Gata4* to induce expression of *Anf* and *Cx43* (which encodes a gap junction protein homologous to *Cx42* in chick) (Bruneau et al., 2001; Habets et al., 2002). The transcriptional repressor *Tbx2* (possibly together with *Tbx3*) disrupts these chamber-specific transcription complexes (Habets et al., 2002; Harrelson et al., 2004) and might operate in the AVC and IC to antagonize chamber-specific differentiation and morphogenesis (Yamada et al., 2000). Therefore, *Bmp2* plays a pivotal role in AVC and IC identity by inducing *Tbx2*. The upstream




Fig. 8. Expansion of the cardiac *Bmp* expression domain in the absence of *Hey2* homologs in mouse and zebrafish embryos. (A,B) *Bmp2* expression marks the AVC and IC of E9.5-E10.0 mouse wild-type (WT) embryos (A), and this region is expanded in homozygous *Hey2* mutant siblings (B). Arrows indicate the borders of *Bmp2* expression. (C) Measurements of the atrioventricular length of the *Bmp2* expression domain relative to head length revealed a 1.7-fold expansion in mutants ($n=5$) relative to wild type ($n=5$; $P<0.005$, Student's *t*-test), compiled from two litters. Error bars correspond to standard deviation. (D,E) *Bmp4* marked the developing AVC (gray arrowheads) in 48 hpf wild-type zebrafish embryos (D), whereas *gridlock* (*grl*) mutant embryos (E), which lack the *Hey2* homolog, showed diffusely distributed *Bmp4* in the AVC and ventricular regions (red arrow), and strong ectopic expression in the inflow tract (blue arrow), as diagrammed in schematics to the right.

signals that regulate *Bmp2* were previously unidentified. We showed that Notch2 and the Hey proteins provide evolutionarily conserved and essential patterning cues for normal spatial localization of *Bmp2* (*Bmp4* in zebrafish) in the looping stage heart, and we propose that this mechanism demarcates the border that separates chamber from AVC and IC myocardium. The genetic hierarchy is summarized in Fig. 9 for chick heart development, showing Notch2-dependent Hey1 expression in the prospective ventricular and atrial regions that




Fig. 9. Diagram of the proposed interactions between Notch2, Hey proteins and Tbx2 in the regulation of Bmp in the chick heart. Hey1 and Hey2 are proposed to function cell autonomously within prospective chamber myocardium to inhibit *Bmp2* expression (*Bmp4* in zebrafish), and thereby suppress AVC and IC identity. Our data indicate that Notch regulates *Hey1* but not *Hey2*, suggesting a Notch-independent input into *Hey2*. Although loss of ventricular *Hey2* expression is seen in *Tbx5*-deficient mouse embryos (Bruneau et al., 2001), *Tbx5* is unable to induce *Hey2* (see Fig. 7), suggesting that any influence on *Hey2* is indirect (as indicated by '?'). An important finding from the present study is that *Tbx2* feeds back to suppress *Hey1* and *Hey2* in the AVC and IC region (Fig. 7), and this mechanism is postulated to sharpen the border with prospective chamber myocardium.

express *Serrate1* and both *Serrate1* and *Serrate2*, respectively. By contrast, *Hey2* is induced independently of Notch in the chick. The expression of Hey proteins in chamber myocardium suppresses *Bmp2* expression, constraining *Bmp2* to the AVC and IC, where it induces *Tbx2*. Furthermore, our finding that *Tbx2* inhibits Hey gene expression suggests a feedback circuit capable of driving the initially graded expression of Hey genes in the early looping heart into a sharp border at the juncture of chamber with AVC and IC myocardium.

Our data implicate both Hey1 and Hey2 as inhibitors of *Bmp2*, but only Hey1 as a direct effector of Notch2 in the chick. Both Hey genes can be Notch regulated: reduction of *Hey1* and *Hey2* mRNA occurs in *Notch1*^{-/-} (Leimeister et al., 2000) and *Dll3*^{-/-} (Dunwoodie et al., 2002) mutant mice, and both *Hey1* and *Hey2* genes have binding sites for CSL and can be upregulated in response to Notch pathway activators such as *N1_{icd}* (Iso et al., 2001; Maier and Gessler, 2000; Nakagawa et al., 2000). Nonetheless, Notch-independent transcription of *Hey1* and *Hey2* genes has also been reported (Iso et al., 2001; Ronés et al., 2002), pointing to the existence of tissue-specific factors that modulate Hey gene responsiveness to CSL and the Notch pathway.

How might Hey genes contribute to congenital cardiac defects such as those present in AGS? *Jagged1* haploinsufficient AGS patients can exhibit atrial and ventricular septal defects and tetralogy of Fallot (Li et al., 1997; McCright et al., 2002; Oda et al., 1997). *Bmp2*, *Bmp4* and *Tbx2* regulate differentiation of the AVC, IC and outflow tract (OFT) regions, so that chamber alignment and development of the valves, septa and conduction system can proceed normally, probably by sustaining the AVC, IC and OFT regions in what has been characterized as an immature, non-chamber state (Moorman and Christoffels, 2003). Our misexpression experiments in chicks, combined with our analyses of mouse *Hey2* and zebrafish *grl* mutants, suggest that attenuation of ventricular *Hey2* or atrial *Hey1* function in human patients would cause an expansion of *Bmp2* into ventricular and atrial myocardium, respectively, which we predict would have patterning and/or morphogenetic consequences for structures that form at the border of the AVC and IC with chamber myocardium. Interestingly, neither *Hey2* mutant mice nor zebrafish *gridlock* mutants showed a corresponding alteration in *Tbx2* and *Tbx2a* or *Tbx2b*, respectively, pointing to the existence of other factors, such as *Tbx20*, that modulate responsiveness downstream of *Bmp*. The morphological consequences of potential genetic interactions between such factors and the genetic cascade

identified here would be best characterized using mouse models of loss of *Notch2*, *Hey* and *Tbx* gene function. Recent studies have demonstrated Notch-dependent endocardial effects on myocardial development (Noseda et al., 2004; Raya et al., 2003; Timmerman et al., 2004), and paracrine effects from endocardial and epicardial sources are well established (Baliga et al., 1999; Ford et al., 1999; Ozcelik et al., 2002; Zhao et al., 1998), underscoring the importance of using tissue-specific misexpression strategies to distinguish intramyocardial effects from confounding indirect effects of Notch components. Accordingly, we are investigating the myocardial role of *Notch2* in the control of *Bmp2* and *Hey* genes, as well as potential downstream *Tbx*, *Iroquois* and *Hand* genes, through the use of specific myocardial conditional mutants that should overcome the severe cardiac anomalies that are present in mouse embryos that have systemic deletions of *Notch2* or Notch signaling components.

In conclusion, our results indicate that *Hey* proteins play an unforeseen role in constraining *Bmp* expression to the AVC and IC during cardiac looping. The data also provide a novel role for *Notch2* in this process directly within the developing myocardium that complements previous studies illustrating Notch function in endocardium. AVC malformations are particularly common, and mutations in *Jagged/Serrate*, *Notch2* and both *Hey* proteins might occur in affected individuals. Indeed, mutations in *Hey1* and *Hey2* have been observed recently in patients with congenital heart disease (Deepak Srivastava, personal communication).

We regret the passing of Tom Maciag, who provided reagents and advice. We thank Derek Kedra for database searching for TBEs and NKEs; and Eric Beyer, Connie Cepko, Jeff Sklar, Deepak Srivastava, Cliff Tabin, Katherine Yutzey and Tom Vogt for providing cDNAs. The authors are grateful to Rolf Bodmer, Seigo Izumo, Fred Levine, Tom Schultheiss, Cliff Tabin, Malcolm Whitman and Ramon Diaz Trelles, and members of the Mercola lab, for many helpful discussions. This research was supported by grants from NIH (R01HL067079, R01HL059502 and R01HL083463) and Exelixis to M.M., the DFG (Ge539/9) to M.G., and NIH (R01HL073348), March of Dimes and American Heart Association to T.P.Z.

References

- Abdelwahid, E., Rice, D., Pelliniemi, L. J. and Jokinen, E. (2001). Overlapping and differential localization of *Bmp-2*, *Bmp-4*, *Msx-2* and apoptosis in the endocardial cushion and adjacent tissues of the developing mouse heart. *Cell Tissue Res.* **305**, 67-78.
- Artavanis-Tsakonas, S., Rand, M. D. and Lake, R. J. (1999). Notch signaling: cell fate control and signal integration in development. *Science* **284**, 770-776.
- Baliga, R. R., Pimental, D. R., Zhao, Y. Y., Simmons, W. W., Marchionni, M. A., Sawyer, D. B. and Kelly, R. A. (1999). NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70(S6K), and MEK-MAPK-RSK. *Am. J. Physiol.* **277**, H2026-H2037.
- Bettenhausen, B., Hrabe de Angelis, M., Simon, D., Guenet, J. L. and Gossler, A. (1995). Transient and restricted expression during mouse embryogenesis of *Dll1*, a murine gene closely related to *Drosophila* *Delta*. *Development* **121**, 2407-2418.
- Brown, D. D., Martz, S. N., Binder, O., Goetz, S. C., Price, B. M., Smith, J. C. and Conlon, F. L. (2005). *Tbx5* and *Tbx20* act synergistically to control vertebrate heart morphogenesis. *Development* **132**, 553-563.
- Bruneau, B. G., Nemer, G., Schmitt, J. P., Charron, F., Robitaille, L., Caron, S., Conner, D. A., Gessler, M., Nemer, M., Seidman, C. E. et al. (2001). A murine model of Holt-Oram syndrome defines roles of the *T-box* transcription factor *Tbx5* in cardiogenesis and disease. *Cell* **106**, 709-721.
- Cai, C. L., Zhou, W., Yang, L., Bu, L., Qyang, Y., Zhang, X., Li, X., Rosenfeld, M. G., Chen, J. and Evans, S. (2005). *T-box* genes coordinate regional rates of proliferation and regional specification during cardiogenesis. *Development* **132**, 2475-2487.
- Chan-Thomas, P. S., Thompson, R. P., Robert, B., Yacoub, M. H. and Barton, P. J. (1993). Expression of homeobox genes *Msx-1* (*Hox-7*) and *Msx-2* (*Hox-8*) during cardiac development in the chick. *Dev. Dyn.* **197**, 203-216.
- Chen, J. N., van Eeden, J. M., Warren, K. S., Chin, A., Nusslein-Volhard, C., Haffter, P. and Fishman, M. C. (1997). Left-right pattern of cardiac *BMP4* may drive asymmetry of the heart in zebrafish. *Development* **124**, 4373-4382.
- Chin, M. T., Maemura, K., Fukumoto, S., Jain, M. K., Layne, M. D., Watanabe, M., Hsieh, C. M. and Lee, M. E. (2000). Cardiovascular basic helix loop helix factor 1, a novel transcriptional repressor expressed preferentially in the developing and adult cardiovascular system. *J. Biol. Chem.* **275**, 6381-6387.
- Conlon, R. A., Reaume, A. G. and Rossant, J. (1995). Notch1 is required for the coordinate segmentation of somites. *Development* **121**, 1533-1545.
- Davis, D. L., Edwards, A. V., Juraszek, A. L., Phelps, A., Wessels, A. and Burch, J. B. (2001). A GATA-6 gene heart-region-specific enhancer provides a novel means to mark and probe a discrete component of the mouse cardiac conduction system. *Mech. Dev.* **108**, 105-119.
- de Jong, F., Opthof, T., Wilde, A. A., Janse, M. J., Charles, R., Lamers, W. H. and Moorman, A. F. (1992). Persisting zones of slow impulse conduction in developing chicken hearts. *Circ. Res.* **71**, 240-250.
- Delorme, B., Dahl, E., Jarry-Guichard, T., Briand, J. P., Willecke, K., Gros, D. and Theveniau-Ruissy, M. (1997). Expression pattern of connexin gene products at the early developmental stages of the mouse cardiovascular system. *Circ. Res.* **81**, 423-437.
- Donovan, J., Kordylewska, A., Jan, Y. N. and Utset, M. F. (2002). Tetralogy of fallot and other congenital heart defects in *Hey2* mutant mice. *Curr. Biol.* **12**, 1605-1610.
- Donoviel, D. B., Hadjantonakis, A.-K., Ikeda, M., Zheng, H., Hyslop, P. and Bernstein, A. (1999). Mice lacking both *presenilin* genes exhibit early embryonic patterning defects. *Genes Dev.* **13**, 2801-2810.
- Dunwoodie, S. L., Henrique, D., Harrison, S. M. and Beddington, R. S. (1997). Mouse *Dll3*: a novel divergent *Delta* gene which may complement the function of other *Delta* homologues during early pattern formation in the mouse embryo. *Development* **124**, 3065-3076.
- Dunwoodie, S. L., Clements, M., Sparrow, D. B., Sa, X., Conlon, R. A. and Beddington, R. S. (2002). Axial skeletal defects caused by mutation in the spondylocostal dysplasia/pudgy gene *Dll3* are associated with disruption of the segmentation clock within the presomitic mesoderm. *Development* **129**, 1795-1806.
- Fischer, A. and Gessler, M. (2003). *Hey* genes in cardiovascular development. *Trends Cardiovasc. Med.* **13**, 221-226.
- Fischer, A., Leimeister, C., Winkler, C., Schumacher, N., Klamt, B., Elmasri, H., Steidl, C., Maier, M., Knobeloch, K. P., Amann, K. et al. (2002). *Hey* bHLH factors in cardiovascular development. *Cold Spring Harb. Symp. Quant. Biol.* **67**, 63-70.
- Fischer, A., Schumacher, N., Maier, M., Sendtner, M. and Gessler, M. (2004). The Notch target genes *Hey1* and *Hey2* are required for embryonic vascular development. *Genes Dev.* **18**, 901-911.
- Fishman, M. C. and Chien, K. R. (1997). Fashioning the vertebrate heart: earliest embryonic decisions. *Development* **124**, 2099-2117.
- Ford, B. D., Loeb, J. A. and Fischbach, G. D. (1999). Neuregulin stimulates DNA synthesis in embryonic chick heart cells. *Dev. Biol.* **214**, 139-150.
- Gessler, M., Knobeloch, K. P., Helisch, A., Amann, K., Schumacher, N., Rohde, E., Fischer, A. and Leimeister, C. (2002). Mouse gridlock: no aortic coarctation or deficiency, but fatal cardiac defects in *Hey2* $-/-$ mice. *Curr. Biol.* **12**, 1601-1604.
- Habets, P. E., Moorman, A. F., Clout, D. E., van Roon, M. A., Lingbeek, M., van Lohuizen, M., Campione, M. and Christoffels, V. M. (2002). Cooperative action of *Tbx2* and *Nkx2.5* inhibits ANF expression in the atrioventricular canal: implications for cardiac chamber formation. *Genes Dev.* **16**, 1234-1246.
- Hamada, Y., Kadokawa, Y., Okabe, M., Ikawa, M., Coleman, J. R. and Tsujimoto, Y. (1999). Mutation in ankyrin repeats of the mouse *Notch2* gene induces early embryonic lethality. *Development* **126**, 3415-3424.
- Hamburger, V. and Hamilton, H. L. (1951). A series of normal stages in the development of the chick embryo. *J. Morphol.* **88**, 49-92.
- Harrelson, Z., Kelly, R. G., Goldin, S. N., Gibson-Brown, J. J., Bollag, R. J., Silver, L. M. and Papaioannou, V. E. (2004). *Tbx2* is essential for patterning the atrioventricular canal and for morphogenesis of the outflow tract during heart development. *Development* **131**, 5041-5052.
- Hayashi, H., Mochii, M., Kodama, R., Hamada, Y., Mizuno, N., Eguchi, G. and Tachi, C. (1996). Isolation of a novel chick homolog of *Serrate* and its coexpression with *C-Notch-1* in chick development. *Int. J. Dev. Biol.* **40**, 1089-1096.
- Henrique, D., Adam, J., Myat, A., Chitnis, A., Lewis, J. and Ish-Horowitz, D. (1995). Expression of a *Delta* homologue in prospective neurons in the chick. *Nature* **375**, 787-790.
- Honjo, T. (1996). The shortest path from the surface to the nucleus: RBP-J kappa/Su(H) transcription factor. *Genes Cells* **1**, 1-9.
- Icardo, J. M. and Fernandez-Teran, A. (1987). Morphologic study of ventricular trabeculation in the embryonic chick heart. *Acta Anat. Basel* **130**, 264-274.
- Iso, T., Sartorelli, V., Chung, G., Shichinohe, T., Kedes, L. and Hamamori, Y. (2001). *HERP*, a new primary target of Notch regulated by ligand binding. *Mol. Cell Biol.* **21**, 6071-6079.
- Iso, T., Kedes, L. and Hamamori, Y. (2003). *HES* and *HERP* families: multiple effectors of the Notch signaling pathway. *J. Cell Physiol.* **194**, 237-255.
- Jarriault, S., Brou, C., Logeat, F., Schroeter, E. H., Kopan, R. and Israel, A. (1995). Signalling downstream of activated mammalian Notch. *Nature* **377**, 355-358.

- Jeffries, S., Robbins, D. J. and Capobianco, A. J. (2002). Characterization of a high-molecular-weight Notch complex in the nucleus of Notch(ic)-transformed RKE cells and in a human T-cell leukemia cell line. *Mol. Cell. Biol.* **22**, 3927-3941.
- Kokubo, H., Lun, Y. and Johnson, R. L. (1999). Identification and expression of a novel family of bHLH cDNAs related to *Drosophila* hairy and enhancer of split. *Biochem. Biophys. Res. Commun.* **260**, 459-465.
- Krantz, I. D., Piccoli, D. A. and Spinner, N. B. (1997). Alagille syndrome. *J. Med. Genet.* **34**, 152-157.
- Kupersmidt, S., Yang, T., Anderson, M. E., Wessels, A., Niswender, K. D., Magnuson, M. A. and Roden, D. M. (1999). Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system. *Circ. Res.* **84**, 146-152.
- Lardelli, M., Dahlstrand, J. and Lendahl, U. (1994). The novel Notch homologue mouse Notch 3 lacks specific epidermal growth factor-repeats and is expressed in proliferating neuroepithelium. *Mech. Dev.* **46**, 123-136.
- Laufer, E., Dahn, R., Orozco, O. E., Yeo, C. Y., Pisenti, J., Henrique, D., Abbott, U. K., Fallon, J. F. and Tabin, C. (1997). Expression of Radical fringe in limb-bud ectoderm regulates apical ectodermal ridge formation. *Nature* **386**, 366-373.
- Leimeister, C., Bach, A. and Gessler, M. (1998). Developmental expression patterns of mouse sFRP genes encoding members of the secreted frizzled related protein family. *Mech. Dev.* **75**, 29-42.
- Leimeister, C., Externbrink, A., Klamt, B. and Gessler, M. (1999). Hey genes: a novel subfamily of hairy- and enhancer of split related genes specifically expressed during mouse embryogenesis. *Mech. Dev.* **85**, 173-177.
- Leimeister, C., Dale, K., Fischer, A., Klamt, B., Hrabe de Angelis, M., Radtke, F., McGrew, M. J., Pourquie, O. and Gessler, M. (2000). Oscillating expression of c-Hey2 in the presomitic mesoderm suggests that the segmentation clock may use combinatorial signaling through multiple interacting bHLH factors. *Dev. Biol.* **227**, 91-103.
- Levin, M., Johnson, R. L., Stern, C. D., Kuehn, M. and Tabin, C. (1995). A molecular pathway determining left-right asymmetry in chick embryogenesis. *Cell* **82**, 803-814.
- Li, L., Krantz, I. D., Deng, Y., Genin, A., Banta, A. B., Collins, C. C., Qi, M., Trask, B. J., Kuo, W. L., Cochran, J. et al. (1997). Alagille syndrome is caused by mutations in human Jagged1, which encodes a ligand for Notch1. *Nat. Genet.* **16**, 243-251.
- Lindsell, C. E., Shawber, C. J., Boulter, J. and Weinmaster, G. (1995). Jagged: a mammalian ligand that activates Notch1. *Cell* **80**, 909-917.
- Maier, M. M. and Gessler, M. (2000). Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new Notch target genes. *Biochem. Biophys. Res. Commun.* **275**, 652-660.
- McCright, B., Gao, X., Shen, L., Lozier, J., Lan, Y., Maguire, M., Herzlinger, D., Weinmaster, G., Jiang, R. and Gridley, T. (2001). Defects in development of the kidney, heart and eye vasculature in mice homozygous for a hypomorphic Notch2 mutation. *Development* **128**, 491-502.
- McCright, B., Lozier, J. and Gridley, T. (2002). A mouse model of Alagille syndrome: Notch2 as a genetic modifier of Jag1 haploinsufficiency. *Development* **129**, 1075-1082.
- Moorman, A. F. and Christoffels, V. M. (2003). Cardiac chamber formation: development, genes, and evolution. *Physiol. Rev.* **83**, 1223-1267.
- Myat, A., Henrique, D., Ish-Horowitz, D. and Lewis, J. (1996). A chick homologue of Serrate and its relationship with Notch and Delta homologues during central neurogenesis. *Dev. Biol.* **174**, 233-247.
- Nakagawa, O., Nakagawa, M., Richardson, J. A., Olson, E. N. and Srivastava, D. (1999). HRT1, HRT2, and HRT3: a new subclass of bHLH transcription factors marking specific cardiac, somitic, and pharyngeal arch segments. *Dev. Biol.* **216**, 72-84.
- Nakagawa, O., McFadden, D. G., Nakagawa, M., Yanagisawa, H., Hu, T., Srivastava, D. and Olson, E. N. (2000). Members of the HRT family of basic helix-loop-helix proteins act as transcriptional repressors downstream of Notch signaling. *Proc. Natl. Acad. Sci. USA* **97**, 13655-13660.
- Nosedá, M., McLean, G., Niessen, K., Chang, L., Pollet, I., Montpetit, R., Shahidi, R., Dorovini-Zis, K., Li, L., Beckstead, B. et al. (2004). Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. *Circ. Res.* **94**, 910-917.
- Oda, T., Elkahoul, A. G., Pike, B. L., Okajima, K., Krantz, I. D., Genin, A., Piccoli, D. A., Meltzer, P. S., Spinner, N. B., Collins, F. S. et al. (1997). Mutations in the human Jagged1 gene are responsible for Alagille syndrome. *Nat. Genet.* **16**, 235-242.
- Oka, C., Nakano, T., Wakeham, A., de la Pompa, J. L., Mori, C., Sakai, T., Okazaki, S., Kawauchi, M., Shiota, K., Mak, T. W. et al. (1995). Disruption of the mouse RBP-J kappa gene results in early embryonic death. *Development* **121**, 3291-3301.
- Ozcelik, C., Erdmann, B., Pilz, B., Wettschureck, N., Britsch, S., Hubner, N., Chien, K. R., Birchmeier, C. and Garratt, A. N. (2002). Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy. *Proc. Natl. Acad. Sci. USA* **99**, 8880-8885.
- Plageman, T. F., Jr and Yutzey, K. E. (2004). Differential expression and function of Tbx5 and Tbx20 in cardiac development. *J. Biol. Chem.* **279**, 19026-19034.
- Raya, A., Koth, C. M., Buscher, D., Kawakami, Y., Itoh, T., Raya, R. M., Sternik, G., Tsai, H. J., Rodriguez-Esteban, C. and Izpisua-Belmonte, J. C. (2003). Activation of Notch signaling pathway precedes heart regeneration in zebrafish. *Proc. Natl. Acad. Sci. USA* **100** Suppl. 1, 11889-11895.
- Rones, M. S., Woda, J., Mercola, M. and McLaughlin, K. A. (2002). Isolation and characterization of Xenopus Hey-1: A downstream mediator of Notch signaling. *Dev. Dyn.* **225**, 554-560.
- Sakata, Y., Kamei, C. N., Nakagami, H., Bronson, R., Liao, J. K. and Chin, M. T. (2002). Ventricular septal defect and cardiomyopathy in mice lacking the transcription factor CHF1/Hey2. *Proc. Natl. Acad. Sci. USA* **99**, 16197-16202.
- Shawber, C., Boulter, J., Lindsell, C. E. and Weinmaster, G. (1996). Jagged2: a serrate-like gene expressed during rat embryogenesis. *Dev. Biol.* **180**, 370-376.
- Shimizu, K., Chiba, S., Saito, T., Kumano, K., Takahashi, T. and Hirai, H. (2001). Manic fringe and lunatic fringe modify different sites of the Notch2 extracellular region, resulting in different signaling modulation. *J. Biol. Chem.* **276**, 25753-25758.
- Shutter, J. R., Scully, S., Fan, W., Richards, W. G., Kitajewski, J., Deblandre, G. A., Kintner, C. R. and Stark, K. L. (2000). Dll4, a novel Notch ligand expressed in arterial endothelium. *Genes Dev.* **14**, 1313-1318.
- Singh, M. K., Christoffels, V. M., Dias, J. M., Trowe, M. O., Petry, M., Schuster-Gossler, K., Burger, A., Ericson, J. and Kispert, A. (2005). Tbx20 is essential for cardiac chamber differentiation and repression of Tbx2. *Development* **132**, 2697-2707.
- Small, D., Kovalenko, D., Soldi, R., Mandinova, A., Kolev, V., Trifonova, R., Bagala, C., Kacer, D., Battelli, C., Liaw, L. et al. (2003). Notch activation suppresses fibroblast growth factor-dependent cellular transformation. *J. Biol. Chem.* **278**, 16405-16413.
- Small, E. M. and Krieg, P. A. (2003). Transgenic analysis of the atrial natriuretic factor (ANF) promoter: Nkx2-5 and GATA-4 binding sites are required for atrial specific expression of ANF. *Dev. Biol.* **261**, 116-131.
- Srivastava, D. and Olson, E. N. (2000). A genetic blueprint for cardiac development. *Nature* **407**, 221-226.
- Stennard, F. A., Costa, M. W., Elliott, D. A., Rankin, S., Haast, S. J., Lai, D., McDonald, L. P., Niederreither, K., Dolle, P., Bruneau, B. G. et al. (2003). Cardiac T-box factor Tbx20 directly interacts with Nkx2-5, GATA4, and GATA5 in regulation of gene expression in the developing heart. *Dev. Biol.* **262**, 206-224.
- Stennard, F. A., Costa, M. W., Lai, D., Biben, C., Furtado, M. B., Solloway, M. J., McCulley, D. J., Leimena, C., Preis, J. I., Dunwoodie, S. L. et al. (2005). Murine T-box transcription factor Tbx20 acts as a repressor during heart development, and is essential for adult heart integrity, function and adaptation. *Development* **132**, 2451-2462.
- Swiatek, P. J., Lindsell, C. E., Franco del Amo, F., Weinmaster, G. and Gridley, T. (1994). Notch1 is essential for postimplantation development in mice. *Genes Dev.* **8**, 707-719.
- Takeuchi, J. K., Mileikovskaia, M., Koshiba-Takeuchi, K., Heidt, A. B., Mori, A. D., Arruda, E. P., Gertsenstein, M., Georges, R., Davidson, L., Mo, R. et al. (2005). Tbx20 dose-dependently regulates transcription factor networks required for mouse heart and motoneuron development. *Development* **132**, 2463-2474.
- Tamura, K., Taniguchi, Y., Minoguchi, S., Sakai, T., Tun, T., Furukawa, T. and Honjo, T. (1995). Physical interaction between a novel domain of the receptor Notch and the transcription factor RBP-J kappa/Su(H). *Curr. Biol.* **5**, 1416-1423.
- Timmerman, L. A., Grego-Bessa, J., Raya, A., Bertran, E., Perez-Pomares, J. M., Diez, J., Aranda, S., Palomo, S., McCormick, F., Izpisua-Belmonte, J. C. et al. (2004). Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. *Genes Dev.* **18**, 99-115.
- Uyttendaele, H., Marazzi, G., Wu, G., Yan, Q., Sassoon, D. and Kitajewski, J. (1996). Notch4/int-3, a mammary proto-oncogene, is an endothelial cell-specific mammalian Notch gene. *Development* **122**, 2251-2259.
- Weinmaster, G. and Kintner, C. (2003). Modulation of Notch signaling during somitogenesis. *Annu. Rev. Cell Dev. Biol.* **19**, 367-395.
- Weinmaster, G., Roberts, V. J. and Lemke, G. (1991). A homolog of *Drosophila* Notch expressed during mammalian development. *Development* **113**, 199-205.
- Weinmaster, G., Roberts, V. J. and Lemke, G. (1992). Notch2: a second mammalian Notch gene. *Development* **116**, 931-941.
- Yamada, M., Revelli, J. P., Eichele, G., Barron, M. and Schwartz, R. J. (2000). Expression of chick Tbx-2, Tbx-3, and Tbx-5 genes during early heart development: evidence for BMP2 induction of Tbx2. *Dev. Biol.* **228**, 95-105.
- Zhao, Y. Y., Sawyer, D. R., Baliga, R. R., Opel, D. J., Han, X., Marchionni, M. A. and Kelly, R. A. (1998). Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. *J. Biol. Chem.* **273**, 10261-10269.
- Zhong, T. P., Rosenberg, M., Mohideen, M.-A. P. K., Weinstein, B. and Fishman, M. C. (2000). gridlock, an HLH gene required for assembly of the aorta in zebrafish. *Science* **287**, 1820-1824.